PL1613296T3 - Sposoby leczenia choroby Parkinsona - Google Patents

Sposoby leczenia choroby Parkinsona

Info

Publication number: PL1613296T3
Authority: PL; Poland
Prior art keywords: parkinson; disease; treatment; methods
Prior art date: 2003-04-11

Application number

PL04726590T

Other languages

English (en)

Inventor

Fariello Ruggero

Carlo Cattaneo

Patricia Salvati

Luca Benatti

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2004-04-08

Publication date

2009-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1613296(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-08 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2009-12-31 Publication of PL1613296T3 publication Critical patent/PL1613296T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04726590T 2003-04-11 2004-04-08 Sposoby leczenia choroby Parkinsona PL1613296T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en)	2003-04-11	2004-04-08	Methods for treatment of parkinson's disease
EP04726590A EP1613296B1 (en)	2003-04-11	2004-04-08	Methods for treatment of parkinson's disease

Publications (1)

Publication Number	Publication Date
PL1613296T3 true PL1613296T3 (pl)	2009-12-31

Family

ID=33159845

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL09154864T PL2070526T3 (pl)	2003-04-11	2004-04-08	Sposoby leczenia choroby Parkinsona
PL04726590T PL1613296T3 (pl)	2003-04-11	2004-04-08	Sposoby leczenia choroby Parkinsona

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL09154864T PL2070526T3 (pl)	2003-04-11	2004-04-08	Sposoby leczenia choroby Parkinsona

Country Status (28)

Country	Link
US (3)	US8283380B2 (pl)
EP (2)	EP1613296B1 (pl)
JP (2)	JP2006522800A (pl)
KR (2)	KR101129015B1 (pl)
CN (2)	CN1771030A (pl)
AR (1)	AR044007A1 (pl)
AT (1)	ATE435012T1 (pl)
AU (1)	AU2004228782B2 (pl)
BR (1)	BRPI0409364A (pl)
CA (1)	CA2523188C (pl)
CY (3)	CY1109295T1 (pl)
DE (1)	DE602004021790D1 (pl)
DK (2)	DK1613296T3 (pl)
ES (2)	ES2454272T3 (pl)
FR (1)	FR15C0054I2 (pl)
HU (1)	HUS1500043I1 (pl)
IL (2)	IL171331A (pl)
LU (1)	LU92782I2 (pl)
MX (1)	MXPA05010873A (pl)
NL (1)	NL300752I2 (pl)
NO (3)	NO334316B1 (pl)
NZ (1)	NZ542910A (pl)
PL (2)	PL2070526T3 (pl)
PT (2)	PT2070526E (pl)
RU (1)	RU2342929C2 (pl)
SI (2)	SI2070526T1 (pl)
TW (1)	TWI340640B (pl)
WO (1)	WO2004089353A2 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) *	2001-09-03	2006-05-31	Newron Pharm Spa	Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
US20070276046A1 (en) *	2003-08-25	2007-11-29	Patricia Salvati	Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
EP1954256A2 (en) *	2005-11-09	2008-08-13	Torrent Pharmaceuticals Ltd	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
SI1963280T1 (sl) *	2005-12-22	2016-02-29	Newron Pharmaceuticals S.P.A.	2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
EP2029524B1 (en)	2006-06-19	2014-11-26	Newron Pharmaceuticals S.p.A.	Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20100092554A1 (en) *	2007-04-24	2010-04-15	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2008151702A1 (en)	2007-06-15	2008-12-18	Newron Pharmaceuticals S.P.A.	Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
US20090149544A1 (en) *	2007-10-22	2009-06-11	Concert Pharmaceuticals, Inc.	Alpha-aminoamide derivatives
LT2229351T (lt)	2007-12-11	2018-01-25	Newron Pharmaceuticals S.P.A.	Didelio grynumo laipsnio 2-[4-(3- arba 2-fluorbenziloksi)benzilamino]propanamidų gamybos būdas
NZ586182A (en) *	2007-12-19	2012-02-24	Newron Pharm Spa	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
US20110027354A1 (en) *	2008-04-01	2011-02-03	Kim Hyoung-Chun	Anti-parkinsonian compounds
CN102203053B (zh) *	2008-06-02	2015-11-25	基因里克斯(英国)有限公司	用于制备胺的改进方法
CN102123980B (zh) *	2008-06-02	2014-05-07	基因里克斯(英国)有限公司	用于制备对映异构纯胺的方法
MX2010013393A (es) *	2008-06-06	2011-06-21	Pharma Two B Ltd	Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
JP2011522892A (ja) *	2008-06-13	2011-08-04	テバファーマシューティカルインダストリーズリミティド	パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
US8080584B2 (en)	2009-01-23	2011-12-20	Teva Pharmaceuticals Industries, Ltd.	Delayed release rasagiline citrate formulation
EP2314569A1 (en)	2009-10-22	2011-04-27	Merck Patent GmbH	Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) *	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide in the treatment of dyskinesia
CA2794389C (en)	2010-04-27	2016-08-23	Newron Pharmaceuticals S.P.A.	Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2011139420A2 (en)	2010-04-30	2011-11-10	Teikoku Pharma Usa, Inc.	Propynylaminoindan transdermal compositions
KR101853082B1 (ko)	2011-03-24	2018-04-27	테이코쿠 팔마 유에스에이, 인코포레이티드	활성제층 및 활성제 변환층을 포함하는 경피 조성물
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
EP2744771B1 (en)	2011-08-19	2020-10-21	The Trustees of Princeton University	C-halogen bond formation
EP2776020B1 (en)	2011-11-09	2019-09-11	Teikoku Seiyaku Co., Ltd.	Methods for the treatment of skin neoplasms
MX2021014782A (es)	2012-10-22	2023-03-23	Civitas Therapeutics Inc	Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
KR20150059177A (ko)	2012-11-02	2015-05-29	테이코쿠 팔마 유에스에이, 인코포레이티드	프로피닐아미노인단 경피 조성물
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
EP3013342B1 (en)	2013-06-27	2021-04-14	Cedars-Sinai Medical Center	Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP3134077A4 (en) *	2014-04-21	2017-12-20	Civitas Therapeutics, Inc.	Rapid relief of motor fluctuations in parkinson's disease
RU2673622C2 (ru) *	2014-10-02	2018-11-29	Мегабайовуд Ко., Лтд.	Соединения альфа-аминоамидных производных и содержащие их фармацевтические композиции
AU2016313138A1 (en) *	2015-08-27	2018-03-15	Prexton Therapeutics Sa	Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
CN109414417A (zh) *	2016-03-17	2019-03-01	约翰·霍普金斯大学	通过paris的法尼基化预防或治疗帕金森症的方法
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) *	2017-01-14	2018-07-19	Mischley Laurie Kathern	Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
CA3072994A1 (en) *	2017-08-17	2019-02-21	Zi-Qiang Gu	Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
US11103457B2 (en)	2017-11-02	2021-08-31	Zambon S.P.A.	Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
CN114727647A (zh) *	2019-09-12	2022-07-08	阿奇维生命科学公司	治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2021109880A1 (zh) *	2019-12-06	2021-06-10	上海医药集团股份有限公司	药物组合物、成套药盒及其应用
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) *	2020-08-31	2022-03-03	Purdue Pharma L.P.	Compositions and methods for levodopa delivery
EP4304457A4 (en) *	2021-03-08	2025-01-08	Prothena Biosciences Limited	TREATMENT OF PARKINSON'S DISEASE
KR102790040B1 (ko) *	2021-06-24	2025-04-01	연세대학교 산학협력단	도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
EP0252290B1 (en) *	1986-06-10	1992-06-03	CHIESI FARMACEUTICI S.p.A.	Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
CA1336169C (en)	1988-03-01	1995-07-04	Walther Birkmayer	Agent for treatment of parkinson's disease
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1996037226A2 (en) *	1995-05-26	1996-11-28	Pfizer Inc.	Combinations for the treatment of parkinsonism containing selective nmda antagonists
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en not_active Ceased
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 EP EP04726590A patent/EP1613296B1/en not_active Expired - Lifetime
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/en not_active Expired - Lifetime
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO2015018I2 (no)	2015-07-23
AU2004228782A1 (en)	2004-10-21
AR044007A1 (es)	2005-08-24
US8283380B2 (en)	2012-10-09
WO2004089353A3 (en)	2004-12-16
US20130053368A1 (en)	2013-02-28
CY1109295T1 (el)	2014-07-02
CN102274517B (zh)	2018-08-31
BRPI0409364A (pt)	2006-04-25
KR101129015B1 (ko)	2012-04-20
NO335537B1 (no)	2014-12-22
NO334316B1 (no)	2014-02-03
LU92782I2 (fr)	2015-09-22
ES2326373T3 (es)	2009-10-08
US9492410B2 (en)	2016-11-15
NO20131417L (no)	2005-12-09
MXPA05010873A (es)	2006-03-21
IL216403A0 (en)	2011-12-29
JP2006522800A (ja)	2006-10-05
NL300752I2 (pl)	2016-07-05
KR20110070929A (ko)	2011-06-24
EP1613296A2 (en)	2006-01-11
CY1115286T1 (el)	2017-01-04
WO2004089353A2 (en)	2004-10-21
SI2070526T1 (sl)	2014-05-30
CN102274517A (zh)	2011-12-14
PL2070526T3 (pl)	2014-08-29
DK1613296T3 (da)	2009-10-05
FR15C0054I1 (fr)	2015-11-09
RU2005131422A (ru)	2006-04-27
CY2015025I1 (el)	2016-04-13
JP2013067647A (ja)	2013-04-18
CY2015025I2 (el)	2016-04-13
DK2070526T3 (da)	2014-03-24
TW200505423A (en)	2005-02-16
CA2523188A1 (en)	2004-10-21
IL171331A (en)	2012-03-29
FR15C0054I2 (fr)	2018-01-26
NZ542910A (en)	2007-10-26
ATE435012T1 (de)	2009-07-15
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
DE602004021790D1 (de)	2009-08-13
NO20054640D0 (no)	2005-10-10
WO2004089353A8 (en)	2005-09-01
IL216403A (en)	2015-01-29
HUS1500043I1 (hu)	2018-11-28
ES2454272T3 (es)	2014-04-10
EP2070526B1 (en)	2014-02-26
CA2523188C (en)	2012-09-25
PT2070526E (pt)	2014-03-31
US8901176B2 (en)	2014-12-02
PT1613296E (pt)	2009-07-30
NO2015018I1 (no)	2015-08-03
RU2342929C2 (ru)	2009-01-10
EP2070526A1 (en)	2009-06-17
EP1613296B1 (en)	2009-07-01
KR20060010745A (ko)	2006-02-02
SI1613296T1 (sl)	2009-10-31
CN1771030A (zh)	2006-05-10
TWI340640B (en)	2011-04-21
US20150150833A1 (en)	2015-06-04
AU2004228782B2 (en)	2010-05-20

Publication	Publication Date	Title
HUS1500043I1 (hu)	2018-11-28	Eljárások Parkinson-kór kezelésére
AU2003286567A8 (en)	2004-05-13	Methods for the treatment of skin disorders
SI2527315T1 (sl)	2014-06-30	Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
AU2003206413A8 (en)	2003-07-24	Substituted amino carboxamides for the treatment of alzheimer's disease
EP1680145A4 (en)	2007-05-23	METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
GB0329874D0 (en)	2004-01-28	Compounds useful for the treatment of diseases
GB0320238D0 (en)	2003-10-01	Treatment of disease
IL173351A0 (en)	2006-06-11	Therapy of ocular disorders
PL371281A1 (pl)	2005-06-13	Sposoby i kompozycje do leczenia chorób oczu
AU2003254146A1 (en)	2005-03-07	Methods for the treatment of parkinson's disease
AU2003228464A1 (en)	2003-12-12	Apparatus for treatment of meniere's disease
AU2003303141A8 (en)	2004-07-22	Hydroxypropyl amides for the treatment of alzheimer's disease
IL180513A0 (en)	2007-06-03	Process for synthesis of 4-4'-diamino-diphenyl-sulfone
AU2003284898A1 (en)	2004-05-25	Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003299101A1 (en)	2004-04-19	Compounds for the treatment of alzheimer's disease
EP1693671A4 (en)	2008-03-19	METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
EP1513550A4 (en)	2006-08-23	NEW BACTERIUM FOR THE TREATMENT OF DISEASES
AU2003277298A8 (en)	2004-05-04	Pharmaceutical compositions for treatment of parkinson's disease
GB0410101D0 (en)	2004-06-09	Parkinson's disease
AU2003297912A8 (en)	2004-07-09	Methods for screening compounds for use in the treatment of disease
GB0327975D0 (en)	2004-01-07	Methods of treatment
AU2003216696A8 (en)	2003-10-27	Methods for the selection of compounds useful for the treatment of huntington's disease
EP1863510A4 (en)	2008-04-02	METHOD FOR TREATING PARKINSON DISEASE
AU2004907196A0 (en)	2005-01-06	Use of Naltrexone for Treating Alzheimer's Disease
AU2003300471A8 (en)	2004-08-10	Methods for treating ocular diseases